welcomeThe King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions. We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.



The FIRST Registry

With the next generation of oral anticoagulants entering clinical practice, the FIRST registry will provide an important data tool to increase knowledge and improve the quality of care of patients with VTE. Read more...

Exemplar Centre Network website


The Exemplar Centre Network website has moved. After being hosted at the King's Thrombosis Centre website since its launch in 2007, the website will now be managed as part of the National VTE prevention Programme and can be accessed by clicking here.

Latest News

  • Anticoagulation news items. Week commencing 27th July 2015
    Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study British Medical Journal…
  • Anticoagulation news items. Week commencing 20th July 2015
    Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti platelet therapy (terminated appraisal) – technology appraisal guidance (TA351) National Institute for…
  • Anticoagulation news items. Week commencing 13th July 2015
    rivaroxaban (Xarelto®) Scottish Medicines Consortium The SMC does not recommend use of rivaroxaban (co-administered with aspirin ± clopidogrel or ticlopidine) within NHS Scotland for the prevention of atherothrombotic events in…